SOLIFENACIN TARTRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H26N2O2.C4H6O6
Molecular Weight	512.5516
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.O=C(O[C@H]1CN2CCC1CC2)N3CCC4=C(C=CC=C4)[C@@H]3C5=CC=CC=C5

InChI

InChIKey=KTNRTEKPBRTUKA-DWERDEDHSA-N

InChI=1S/C23H26N2O2.C4H6O6/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-1(3(7)8)2(6)4(9)10/h1-9,18,21-22H,10-16H2;1-2,5-6H,(H,7,8)(H,9,10)/t21-,22-;1-,2-/m01/s1

HIDE SMILES / InChI

Molecular Formula	C4H6O6
Molecular Weight	150.0868
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C23H26N2O2
Molecular Weight	362.4647
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/vesicare-drug.htm https://www.drugs.com/mtm/solifenacin.html http://www.wikidoc.org/index.php/Solifenacin

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15190387 \| https://www.ncbi.nlm.nih.gov/pubmed/16465186 \| https://www.ncbi.nlm.nih.gov/pubmed/19446545 \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2849	10.0 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/16465186 \| https://www.ncbi.nlm.nih.gov/pubmed/19446545 \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2849	125.0 nM [Ki]
Muscarinic acetylcholine receptor M1 168 Target ID: CHEMBL216 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/16465186 \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2849	25.0 nM [Ki]
Muscarinic acetylcholine receptor M4 87 Target ID: CHEMBL1821 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2849	7.73 null [pKi]
Muscarinic acetylcholine receptor M5 63 Target ID: CHEMBL2035 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2849	7.46 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf	Primary		Approved 8583	VESICARE Approved Use VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1) Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
14.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
820 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
50.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf			SOLIFENACIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15317830	healthy, 19-40 Health Status: healthy Age Group: 19-40 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/15317830	Sources: https://pubmed.ncbi.nlm.nih.gov/15317830
30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15317830	healthy, 20-35 Health Status: healthy Age Group: 20-35 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/15317830	Sources: https://pubmed.ncbi.nlm.nih.gov/15317830
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	Disc. AE: Angioedema, Anaphylactic reaction... AEs leading to discontinuation/dose reduction: Angioedema Anaphylactic reaction (rare) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	Disc. AE: Dry mouth... AEs leading to discontinuation/dose reduction: Dry mouth (1.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf

AEs

AE	Significance	Dose	Population
Angioedema	Disc. AE	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf
Anaphylactic reaction	rare Disc. AE	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf
Dry mouth	1.5% Disc. AE	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A 70 CYP2C19 2057	CYP2C19 1119 CYP3A5 446 CYP2C8 810 CYP1A1 389 P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A 122	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	yes [Inhibition 1.04 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=22 Page: 22,52	major	yes (co-administration study) Comment: Label: coadministration with ketoconazole increased the mean Cmax and AUC of solifenacin by 1.5 and 2.7 fold, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=22 Page: 22,52
CYP1A1 389	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=22 Page: 22,27	minor
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
P-gp 2052	substrate 4014 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2011.03961.x	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_pharmr.pdf#page=35 Page: 35.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY543715	https://www.001chemical.com/chem/242478-37-1
AA Blocks	AA019FPZ	https://www.aablocks.com/goods/Goods/detail?id=AA019FPZ
Aaron Chemicals	AR019GHR	http://www.aaronchem.com/242478-37-1
Acadechem	ACDX-012562	http://acadechemical.com/product/87283
Achemo Scientific Limited	AC-63428	http://www.achemo.com/search/?Keyword= 242478-37-1
Achemtek	0102-022129	http://www.achemtek.com/242478-37-1
Acorn PharmaTech	ACN-037989	http://www.acornpharmatech.com/
Adooq BioScience	A16947	https://www.adooq.com/solifenacin.html
AK Scientific, Inc. (AKSCI)	X4689	http://www.aksci.com/item_detail.php?cat=X4689
Alfa Chemistry	242478-37-1	https://www.alfa-chemistry.com/cas_242478-37-1.htm
Alfa Chemistry	ACM180272144	https://www.alfa-chemistry.com/solifenacin-cas-180272-14-4-item-285040.htm
Alichem	189007421	http://www.alichem.com/en/products/180272-14-4.html
Ambinter	Amb20241303	http://www.ambinter.com/reference/20241303
Aurora Fine Chemicals LLC	K16.645.638	http://online.aurorafinechemicals.com/info?ID=K16.645.638
AvaChem Scientific	2557B	http://www.avachem.com/productSearch.asp?2557B
BLD Pharm	BD151698	http://www.bldpharm.com/products/242478-37-1.html
BLD Pharm	BD764111	http://www.bldpharm.com/products/180272-14-4.html
Capot Chemical	23264	http://www.capotchem.com/en/23264.htm
Capot Chemical	PubChem23264	http://www.capotchem.com/en/23264.htm
Chem Scene	CS-8096	http://www.chemscene.com/242478-37-1.html
Chemenu	CM126714	http://www.chemenu.com/products/CM126714
ChemMol	49419563	http://www.chemmol.com/chemmol/49419563.html
Chemspace	CSSB00138412639	https://chem-space.com/CSSB00138412639
Chemspace	CSSS00020667699	https://chem-space.com/CSSS00020667699
Chemspace	CSSS00102523311	https://chem-space.com/CSSS00102523311
Chemspace	CSSS00116206880	https://chem-space.com/CSSS00116206880
CSNpharm	CSN21835	https://www.csnpharm.com/products/solifenacin.html
DC Chemicals	DC9214	http://www.dcchemicals.com/product_show-Solifenacin.html
Debye Scientific	DB-001095	http://www.debyesci.com/DB-001095.html
eNovation Chemicals	D591419	https://www.enovationchem.com/ProductDetails.asp?ProductID=D591419
eNovation Chemicals	D775303	https://www.enovationchem.com/ProductDetails.asp?ProductID=D775303
eNovation Chemicals	D962251	https://www.enovationchem.com/ProductDetails.asp?ProductID=D962251
Excenen	EX-A4180	https://www.excenen.com/searchresultlist.php?id=EX-A4180
Finetech	FT-0698075	http://www.finetechnology-ind.com/prod/detail/pub/242478-37-1.html
Finetech	FT-0778252	https://www.finetechnology-ind.com/prod/detail/pub/180272-14-4.html
Hairui	HR112258	http://www.hairuichem.com/en/product/242478-37-1.html
iChemical	EBD2197604	http://www.ichemical.com/products/242478-37-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01345685	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01345685
MedChem Express	HY-A0034	https://www.medchemexpress.com/Solifenacin.html
Molcore	MC543715	https://www.molcore.com/product/242478-37-1
MolPort	MolPort-023-220-809	https://www.molport.com/shop/molecule-link/MolPort-023-220-809
MolPort	MolPort-046-871-055	https://www.molport.com/shop/molecule-link/MolPort-046-871-055
MuseChem	I012990	https://www.musechem.com/product/I012990.html
OChem	25997	http://www.ocheminc.com/index.php?act=psearch&pid=478S382
Smolecule	S006668	http://www.smolecule.com/products/s006668
Smolecule	S598639	https://www.smolecule.com/products/s598639
Smolecule	S635527	https://www.smolecule.com/products/s635527
Specs	AR-270/43507775	http://www.specs.net/enter.php?specsid=AR-270/43507775
Synblock Inc	SB17427	http://www.synblock.com/product/242478-37-1.html
THE BioTek	bt-255435	https://www.thebiotek.com/product/inhibitors/bt-255435
THE BioTek	bt-339594	https://www.thebiotek.com/product/others/bt-339594
Vitas-M Laboratory	STL484275	http://www.request.vitasmlab.com/index.php?option=com_search_stk&Itemid=22&stk=STL484275&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Yuhao Chemical	YH48847	http://www.chemyuhao.com/242478-37-1.html

PubMed

Title	Date	PubMed
An unusual cause of postoperative detrusor overactivity.	2007-10	17333438
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.	2007-09	17211528
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.	2007-07	17131169
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.	2007-03	17341526
Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.	2007-02-28	17207478
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.	2007-01	17251687
Redefining response in overactive bladder syndrome.	2007-01	17227496
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.	2007-01	17202659
Newer agents for the management of overactive bladder.	2006-12-15	17186712
New developments in the treatment of urinary incontinence.	2006-12	17268395
Solifenacin succinate (VESIcare): overactive bladder therapy.	2006-12	17253085
Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.	2006-12	17170513
[Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].	2006-12	17167217
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.	2006-12	17125433
Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.	2006-12	17109616
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).	2006-11	17213014
Gateways to clinical trials.	2006-11	17200730
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?	2006-11	17021853
Solifenacin.	2006-11	17011384
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.	2006-10-18	17054185
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.	2006-09	17062331
Solifenacin succinate for the treatment of symptoms of overactive bladder.	2006-09	17062299
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.	2006-09	16625311
Gateways to clinical trials.	2006-08-09	16894408
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.	2006-08	16908335
Solifenacin significantly improves all symptoms of overactive bladder syndrome.	2006-08	16893438
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.	2006-08	16842396
Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.	2006-07	16867168
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.	2006-07	16819176
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].	2006-07	16816976
[Oral anticholinergics in overactive bladder].	2006-07	16791627
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.	2006-06	16686722
Gateways to clinical trials.	2006-05	16801985
Gateways to clinical trials.	2006-04	16810345
The causes and consequences of overactive bladder.	2006-04	16620184
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.	2006-03	16730617
The emergence of new drugs for overactive bladder.	2006-03	16503831
Management of overactive bladder and urge urinary incontinence in the elderly patient.	2006-03	16483866
Pharmacologic management of overactive bladder: practical options for the primary care physician.	2006-03	16483865
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.	2006-03	16483863
Muscarinic receptors in the bladder: from basic research to therapeutics.	2006-02	16465186
New drugs 06, part I.	2006-02	16462265
Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.	2006-01	16393429
Solifenacin in overactive bladder syndrome.	2006	16451092
[Drug discovery in the fields of urology: tamsulosin and solifenacin].	2005-11	16394579
Solifenacin in overactive bladder: a viewpoint by Hashim Hashim.	2005	16363889
Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels.	2005	16363888
Solifenacin in overactive bladder syndrome.	2005	16363887
Overactive bladder in the elderly: a guide to pharmacological management.	2005	16363885
Drug forecast--solifenacin: an investigational anticholinergic for overactive bladder.	2004-05	16553482

Patents

Sample Use Guides

In Vivo Use Guide

5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 02:53:35 GMT 2025` Edited by `admin` on `Wed Apr 02 02:53:35 GMT 2025`
Record UNII	CCM244AP8R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SOLIFENACIN TARTRATE

Common Name

English

SOLIFENACIN BITARTRATE

Preferred Name

English

Solifenacin tartrate [WHO-DD]

Common Name

English

SOLIFENACIN HYDROGEN TARTRATE

Common Name

English

2(1H)-ISOQUINOLINECARBOXYLIC ACID, 3,4-DIHYDRO-1-PHENYL-, (3R)-1-AZABICYCLO(2.2.2)OCT-3-YL ESTER, (1S)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1)

Systematic Name

English

Code System Code Type Description

FDA UNII

CCM244AP8R

Created by admin on Wed Apr 02 02:53:35 GMT 2025 , Edited by admin on Wed Apr 02 02:53:35 GMT 2025

PRIMARY

CAS

1035547-81-9

Created by admin on Wed Apr 02 02:53:35 GMT 2025 , Edited by admin on Wed Apr 02 02:53:35 GMT 2025

PRIMARY

PUBCHEM

154731572

Created by admin on Wed Apr 02 02:53:35 GMT 2025 , Edited by admin on Wed Apr 02 02:53:35 GMT 2025

PRIMARY

Related Record Type Details


					A8910SQJ1U

SOLIFENACIN

PARENT -> SALT/SOLVATE

Related Record Type Details


					A8910SQJ1U

SOLIFENACIN

ACTIVE MOIETY

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator